標(biāo)題: Titlebook: Hormone Related Cancer Mechanistic and Nanomedicines; Challenges and Prosp Mahfoozur Rahman,Waleed H Almalki,Khalid S Alharbi Book 2022 The [打印本頁] 作者: CHORD 時間: 2025-3-21 17:06
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines影響因子(影響力)
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines影響因子(影響力)學(xué)科排名
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines網(wǎng)絡(luò)公開度
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines被引頻次
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines被引頻次學(xué)科排名
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines年度引用
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines年度引用學(xué)科排名
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines讀者反饋
書目名稱Hormone Related Cancer Mechanistic and Nanomedicines讀者反饋學(xué)科排名
作者: 招人嫉妒 時間: 2025-3-21 23:11 作者: 減弱不好 時間: 2025-3-22 01:29 作者: 甜食 時間: 2025-3-22 05:04 作者: 治愈 時間: 2025-3-22 10:01
Vivek Dwivedi,Shahnawaz Sameem,Mahfoozur Rahman,Prateek Pathak,Amita Vermade in den ASEAN-Staaten betrachtet man den Automobilbau als Schlüsselindustrie, die von den Regierungen in diesen L?ndern gef?rdert wird. Der japanischen Automobilindustrie ist es schon frühzeitig gelungen, sich in den südostasiatischen M?rkten zu etablieren und Produktionsnetzwerke innerhalb der Re作者: 瑪瑙 時間: 2025-3-22 15:53 作者: 做方舟 時間: 2025-3-22 18:11 作者: avenge 時間: 2025-3-22 21:40
Progress of Cancer Nano Medicine, Clinical Hurdles, and Opportunities,vity. Nanomedicine for cancer treatment given intravenously to avoid renal clearance cannot pass through tight endothelial junctions in normal blood arteries and accumulate in plasma at high levels. In this chapter, we will look at the advancements of nanomedicine in all areas of pharmaceuticals. We作者: 樹木心 時間: 2025-3-23 05:01
Emergence of Nanohybrids in Hormonal Cancer-Targeted Therapy,han conventional chemotherapeutics while also being less toxic to healthy cells. This is due to the carriers’ improved enhanced permeability and retention effect (EPR), as well as their active cellular uptake. Nano-carriers containing chemotherapeutic drugs can be conjugated with molecules that bind作者: ARY 時間: 2025-3-23 06:45 作者: BAN 時間: 2025-3-23 13:37
Pancreatic Cancer: Nanoparticle Targeted Therapy Via Epidermal Growth Factor Receptor,tough to detect, hard to diagnose, and early to metastasize. Hence, by the time symptoms are diagnosed it may be at higher phases and could have been spread to other organs. Pancreatic cancer is a malignant neoplasm that arises from the cells of pancreas, a glandular organ made of both endocrine and作者: emulsify 時間: 2025-3-23 17:53
Nanocarriers-Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead,lity have been steadily increasing. Over the last decade, advancements in diagnosis, pancreatectomy surgery, radiotherapy technique, and systemic therapies have made advances, but relatively small improvements in patient outcomes. Furthermore, in pancreatic cancer, most of the chemotherapy drugs res作者: 遺產(chǎn) 時間: 2025-3-23 18:29
Pancreatic Cancer Treatment by Using Theragnostic Nanoparticles,rious approaches have been implemented for the detection of PC at an early stage. Apart from this several chemotherapeutic drugs are suggested for patients diagnosed with PC but their applications are restricted due to systemic toxicity due to long-term usage. Nanotechnology-based therapeutic approa作者: 破譯密碼 時間: 2025-3-24 00:28
Nanomedicine-Based Combinational Therapy for Breast Cancer,ficient to cater to this fatal disease. The complex pathophysiology of the disease demands multidrug therapy or combinational drug therapy, in which the two drugs show the nonoverlapping mode of action. Drug combinations such as doxorubicin and cyclophosphamide, bevacizumab and paclitaxel, lapatinib作者: rods366 時間: 2025-3-24 02:49
Nanoliposomal System for Breast Cancer Therapy,into clinical applications. Liposomes are well-established and effective drug delivery systems, extensively used in cancer therapy including breast cancer. In this chapter nanoliposomes designed with the breast cancer targeting feature and drug release triggering functions are emphasized. The chapte作者: OUTRE 時間: 2025-3-24 07:42
Conventional to Nanotherapeutic Strategies against Triple-Negative Breast Cancer, and human epidermal growth factor receptor-2. In the past several decades, the absence of specific targets resulted in a shortage of innovative treatments, and chemotherapy remained the dominant treatment option. However, TNBC has a lower survival rate and an increased likelihood of recurrence and 作者: inculpate 時間: 2025-3-24 13:15 作者: BUOY 時間: 2025-3-24 18:01
Concept of Nanomedicine in Endocrine Hormone Cancer Treatment,er and badly affects the endocrine system of the patient. Currently, due to the alarming increase in the endocrine cancer patients, there is a need for nanotechnology like therapeutic options to treat the endocrine cancer. This chapter describes about the steroid-based hormone receptors in the cance作者: Congeal 時間: 2025-3-24 23:00
Neurocognitive Underpinning of Neurological Disorders: Role of Default Mode Network,ted with many neurological disorders. However, this network has recently shown activation during high-order social cognitive tasks attributed to self-referential processing and theory of mind. Furthermore, in several disorders with deficits in social cognition, or disrupted physiology including auti作者: Estrogen 時間: 2025-3-25 00:45 作者: commensurate 時間: 2025-3-25 04:54 作者: malign 時間: 2025-3-25 11:21 作者: Paradox 時間: 2025-3-25 11:50 作者: Ingratiate 時間: 2025-3-25 19:28
Ankit Sahoo,Kainat Alam,Shipra Daniel,Sarwar Beg,Vikas Kumar,Abdul Hafeez,Mahfoozur Rahman,Waleed H.作者: 哪有黃油 時間: 2025-3-25 23:36 作者: 共同生活 時間: 2025-3-26 03:11
Pooja Jain,Nazia Hassan,Uzma Farooq,Sradhanjali Mohapatra,Thomson Santosh Alex,Mahak Fatima,Mohd Aam作者: FECK 時間: 2025-3-26 06:31
Gulam Mustafa,Mohammad Zaki Ahmad,Mohammed Aslam,Anuj Garg,Javed Ahmad作者: 顧客 時間: 2025-3-26 09:31
Srushti Tambe,Sabya Sachi Das,Neeru Singh,Priya Ranjan Prasad Verma,Purnima Amin,Sandeep Kumar Singh作者: recede 時間: 2025-3-26 13:42 作者: eczema 時間: 2025-3-26 17:04 作者: 就職 時間: 2025-3-26 23:49
Md Akbar,Hasan Ali,Shweta Srivastav,Kainat Alam,Shipra Daniel,Faraat Ali作者: 尋找 時間: 2025-3-27 01:54 作者: 苦笑 時間: 2025-3-27 06:11 作者: 高原 時間: 2025-3-27 12:20
Conventional to Nanoscale-Based Carrier Systems in the Management of Ovarian Cancer,ability, and prolonged therapeutic regimen. Thus, to overcome these limitations nanotherapeutic approaches can be used for the effective delivery of drugs with superior targetability and negligible or no toxicity. In this chapter, we have discussed the major molecular pathways and cellular targets c作者: enormous 時間: 2025-3-27 15:05 作者: 值得尊敬 時間: 2025-3-27 18:29 作者: adumbrate 時間: 2025-3-27 22:32 作者: 高度 時間: 2025-3-28 05:59 作者: 抱負 時間: 2025-3-28 06:46
Neuroendocrine Carcinoma of Endometrium Convention Treatment Approach to Nanomedicine,e female genital tract are aggressive and rare tumours that usually involve the cervix and ovary, and are seen rarely in the endometrium in perimenopausal or postmenopausal women But, their prospective role in gNECs still remains uncertain because of the small prevalence. Few subjective proofs exist作者: Mitigate 時間: 2025-3-28 12:20 作者: Metastasis 時間: 2025-3-28 18:29
Regulatory Landscapes in Approval of Cancer Vaccines,in this field. Hence, bilateral talks with the regulatory body are mandatory requirement to discuss and deliberate the clinical development plan on case-by-case basis. Thereby, the specific issues related to the quality of product under development are taken into consideration. All such regulatory a作者: 中國紀(jì)念碑 時間: 2025-3-28 22:08
Hormone Related Cancer Mechanistic and NanomedicinesChallenges and Prosp作者: 有毛就脫毛 時間: 2025-3-29 01:08
Hormone Related Cancer Mechanistic and Nanomedicines978-981-19-5558-7作者: 埋葬 時間: 2025-3-29 04:40
his book covers?the progress made in hormone-related cancer and their management by nonmedicinal therapy for targeting the hormone regulated cancer with their clinical progress and clinical hurdles..978-981-19-5560-0978-981-19-5558-7作者: LUDE 時間: 2025-3-29 09:04
ann von einer weiteren Z?sur der internationalen Automobilindustrie gesprochen werden. Hier sind es nicht vollst?ndig neue Organisations- und Produktionskonzepte, sondern die Auswirkungen von Ver?nderungen der Marktstrukturen, die als neue Umweltbedingungen auf ?konomische Entscheidungen einwirken (作者: Jocose 時間: 2025-3-29 14:53
Mahfoozur Rahman,Kainat Alam,Shipra Daniel,Afroze Alam,Sarwar Begann von einer weiteren Z?sur der internationalen Automobilindustrie gesprochen werden. Hier sind es nicht vollst?ndig neue Organisations- und Produktionskonzepte, sondern die Auswirkungen von Ver?nderungen der Marktstrukturen, die als neue Umweltbedingungen auf ?konomische Entscheidungen einwirken (作者: photophobia 時間: 2025-3-29 18:01 作者: 陰險 時間: 2025-3-29 23:13
Sabya Sachi Das,Ishan Moitra,Subhrajeet Das,Neeru Singh,Priya Ranjan Prasad Verma,Sandeep Kumar Sing einen Zeitraum von zwei Jahren dasselbe Produkt herstellen darf. Zwei Jahre sp?ter ist das Industrial Joint Venture Programm verabschiedet worden (IJVP). Dies war das erste Programm, das den Unternehmen Steuervorteile garantierte, die sich in den Mitgliedsl?ndern an ausgew?hlten Industrieprogrammen作者: VICT 時間: 2025-3-30 01:58 作者: chronicle 時間: 2025-3-30 04:28 作者: 雇傭兵 時間: 2025-3-30 10:32 作者: GRATE 時間: 2025-3-30 15:03 作者: grieve 時間: 2025-3-30 17:20 作者: construct 時間: 2025-3-31 00:26
Book 2022g the imaging and drug delivery functions in one single nanoformulation, providing vital insights into the identification of tumour and predicting the efficacy of nanomedicine. For its unique properties, which include their small size and biocompatibility and ability to permeate the cellular membran作者: 典型 時間: 2025-3-31 01:53
Progress of Cancer Nano Medicine, Clinical Hurdles, and Opportunities,rteries and accumulate in plasma at high levels. In this chapter, we will look at the advancements of nanomedicine in all areas of pharmaceuticals. We will also discuss the challenges encountered during clinical testing and development of cancer medicines, as well as future opportunities.作者: 熒光 時間: 2025-3-31 06:25
Challenges and Opportunities in the Delivery of Oral Anticancer Therapeutics,ilability, pharmacokinetics, and biodistribution profiles. Here, we define the drug delivery challenges related to oral routes of administration and review innovative DDS, marketed or in development, that answer those challenges.作者: Ophthalmoscope 時間: 2025-3-31 11:19
Nanocarriers-Based Targeted Therapies for Pancreatic Cancer and Challenges Ahead,sis. Recently, significant attempts have been made to provide targeted-based nanocarriers to treat pancreatic cancer. This chapter tries to give information about the new possibilities of targeting pancreatic cancer via nanocarriers and challenges ahead.
